Successful induction of long-term remission using rituximab in a patient with refractory hairy cell leukemia-Japanese variant

International Journal of Hematology

Volumn 80, Issue 5, 2004, Pages 432-434

  Imamura, Tomoyuki ^a   Ohtsuka, Eiichi ^a   Ogata, Masao ^a   Oka, Fuyuko ^a   Kashima, Kenji ^a   Kikuchi, Hiroshi ^a   Nasu, Masaru ^a  

^a OITA UNIVERSITY   (Japan)

Author keywords

Hairy cell leukemia Japanese variant; Nucleoside analogs; Rituximab

Indexed keywords

CLADRIBINE; PENTOSTATIN; RITUXIMAB;

AGED; ARTICLE; CANCER REGRESSION; CANCER RESISTANCE; CASE REPORT; DRUG EFFICACY; HAIRY CELL LEUKEMIA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LONG TERM CARE; MALE; SALVAGE THERAPY; SPLEEN; SPLENECTOMY; THROMBOCYTOPENIA;

AGED; ANTIBIOTICS, ANTINEOPLASTIC; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLADRIBINE; DRUG THERAPY, COMBINATION; HUMANS; JAPAN; LEUKEMIA, HAIRY CELL; MALE; PENTOSTATIN; REMISSION INDUCTION;

EID: 11144224061     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.04078     Document Type: Article

References (24)

1. Bouroncle BA, Wiseman BK, Doan CA. Leukemic reticuloendotheliosis. Blood. 1958;13:609-630.
2. Yam LT, Li CY, Lam KW. Tartrate-resistant acid phosphatase isoenzyme in the reticulum cells of leukemic reticuloendothelisosis. N Engl J Med. 1971;284:357-360.
3. Korsmeyer SJ, Greene WC, Cossman J, et al. Rearrangement and expression of immunoglobulin genes and expression of Tac antigen in hairy cell leukemia. Proc Natl Acad Sci U S A. 1983;80:4522-4526.
4. Schwarting R, Stein H, Wang CY. The monoclonal antibodies alpha S-HCL 1(alpha Leu-14) and alpha S-HCL 3(alpha Leu-M5) allow the diagnosis of hairy cell leukemia. Blood. 1985;65:974-983.
5. Quesada JR, Hersh EM, Manning J, et al. Treatment of hairy cell leukemia with recombinant alpha-interferon. Blood. 1986;68:493-497.
6. Ho AD, Thaler J, Mandelli F, et al. Response to pentostatin in hairy-cell leukemia refractory to interferon-alpha. The European Organization for Research and Treatment of Cancer Leukemia Cooperative Group. J Clin Oncol. 1989;7:1533-1538.
7. Grever M, Kopecky K, Foucar MK, et al. Randomized comparison of pentostatin versus interferon alpha-2a in previously untreated patients with hairy cell leukemia: an intergroup study. J Oncol. 1995;13:974-982.
8. Piro LD, Carrera CJ, Carson DA, Beutler E. Lasting remission in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med. 1990;322:1117-1121.
9. Cheson BD, Sorensen JM, Vena DA, et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the group C protocol mechanism of the National Cancer Institute: a report of 979 patients. J Clin Oncol. 1998;16:3007-3015.
10. Machii T, Tokumine Y, Inoue R, Kitani T. Predominance of a distinct subtype of hairy cell leukemia in Japan. Leukemia. 1993;7:181-186.
11. Yamaguchi M, Machii T, Shibayama H, et al. Immunophenotypic features and configuration of immunoglobulin genes in hairy cell leukemia-Japanese variant. Leukemia. 1996;10:1390-1394.
12. Machii T, Kitani T, Kimura K, et al. Interferon-alpha therapy for hairy cell leukemia and lymphoproliferative disorders simulating hairy cell leukemia (hairy cell leukemia variant): a cooperative group study in Japan [in Japanese]. Rinsho Ketsueki. 1988;29:2029-2036.
13. Shimoyama M, Tobinai K, Yamaguchi K, et al. Treatment of hairy cell leukemia with deoxycoformycin (YK-176). The Deoxycoformycin (YK-176) Study Group. Jpn J Clin Oncol. 1992;22:406-410.
14. Grillo-Lopez AJ. Monoclonal antibody therapy for B-cell lymphoma. Int J Hematol. 2002;76:385-393.
15. Hagberg H, Lundholm L. Rituximab, a chimaeric anti-CD20 monoclonal antibody, in the treatment of hairy cell leukemia. Br J Haematol. 2001;115:609-611.
16. Pollio F, Pocali B, Palmieri S, et al. Rituximab: a useful drug for a repeatedly relapsed hairy cell leukemia patient. Ann Hematol. 2002;81:736-738.
17. Mey U, Strehl J, Gorschluter M, et al. Advances in the treatment of hairy-cell leukemia. Lancet Oncol. 2003;4:86-94.
18. Nieva J, Bethel K, Saven A. Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia. Blood. 2003;102:810-813.
19. Thomas DA, O'Brien S, Bueso-Ramos C, et al. Rituximab in relapsed or refractory hairy cell leukemia. Blood. 2003;102:3906-3911.
20. Legrand O, Vekhoff A, Marie JP, Zittoun R, Delmer A. Treatment of hairy cell leukemia (HCL) with 2-chlorodeoxyadenosine(2-CdA): identification of parameters predictive of adverse effects. Br J Haematol. 1997;99:165-167.
21. Cawley JC, Burns GF, Hayhoe FG, et al. A chronic lymphoproliferative disorder with distinctive features: a distinct variant of hairy cell leukemia. Leuk Res. 1980;4:547-559.
22. Isaacson PG, Matutes E, Burke M, et al. The histopathology of splenic lymphoma with villous lymphocytes. Blood. 1994;84:3828-3834.
23. Cheson BD. Infectious and immunosuppressive complications of purine analog therapy. J Clin Oncol. 1995;13:2431-2448.
24. Betticher DC, Fey MF, von Rohr A, et al. High incidence of infections after 2-chlorodeoxyadenosine(2-CDA) therapy in patients with malignant lymphomas and chronic and acute leukaemias. Ann Oncol. 1994;5:57-64.